Header Image

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes to treat rare diseases.

RAPIVAB FDA Approved December 2014

RAPIVAB Approved by Health Canada January 2017

RAPIVAB licensed to CSL (now Seqirus) for the treatment of influenza June 2015

Learn More

To learn more about BioCryst Pharmaceuticals please read the company’s 2016 10K annual report and 2017 proxy.

Read our annual reportRead our proxy

BioCryst's core development programs include BCX7353 and other 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema and BCX4430, a broad spectrum antiviral for hemorrhagic fevers.

Learn more about BioCryst’s broad spectrum antiviral BCX4430, a potential medical countermeasure for filoviruses.